• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: Director Hively Brad bought $47,168 worth of shares (45,280 units at $1.04), increasing direct ownership by 7% to 712,033 units (SEC Form 4)

    4/28/25 7:20:14 PM ET
    $TOI
    Medical/Nursing Services
    Health Care
    Get the next $TOI alert in real time by email
    SEC FORM 4/A SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Hively Brad

    (Last) (First) (Middle)
    C/O THE ONCOLOGY INSTITUTE INC.
    18000 STUDEBAKER ROAD, SUITE 800

    (Street)
    CERRITOS CA 90703

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Oncology Institute, Inc. [ TOI ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    03/26/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    03/28/2025
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 03/26/2025 P(2)(3) 45,280(1) A $1.0417(4) 712,033 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Common Warrant(2) $1.198 03/26/2025 P(2)(3) 22,640(1) 03/26/2025(5) 03/26/2030 Common Stock 22,640(1) $0.125(4) 22,640 D
    Explanation of Responses:
    1. This amendment is filed to correct the number of shares of Common Stock and number of Common Warrants acquired by the reporting person in the transaction reported on the original Form 4 filed on March 28, 2025. As a result of this correction, the amount of securities beneficially owned following the reported transaction specified in Table I, Column 5 and Table II, Column 9 have also been corrected.
    2. Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the "Private Placement"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued the reporting person Private Placement units consisting of two shares of the Company's common stock ("Common Stock") and a common warrant ("Common Warrant") to purchase one share of Common Stock (the "Private Placement Unit").
    3. The issuance of the securities to the reporting person pursuant to the Private Placement was approved by the Company's board of directors and was deemed an exempt transaction pursuant to Rule 16b-3 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").
    4. Each Private Placement Unit was purchased at a price of $2.2084 per unit, with a cost per share of Common Stock of $1.0417 and a cost per Common Warrant of $0.1250.
    5. The reporting person may not exercise any portion of a Common Warrant to the extent that the reporting person would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately prior to or after giving effect to such exercise, as such percentage ownership is determined in accordance with Section 13(d) under the Exchange Act.
    /s/ Mark Hueppelsheuser, Attorney-in-Fact for Brad Hively 04/28/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $TOI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TOI

    DatePrice TargetRatingAnalyst
    5/15/2025$7.00Buy
    BTIG Research
    2/26/2024$2.50Buy
    Jefferies
    9/14/2022$7.00Buy
    Guggenheim
    8/15/2022$10.00Buy
    Jefferies
    More analyst ratings

    $TOI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • The Oncology Institute set to join the Russell 2000® and Russell 3000® Indexes

      CERRITOS, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI"), one of the largest value-based oncology groups in the United States, today announced that it will join the Russell 2000® and Russell 3000® after the 2025 Russell indexes annual reconstitution, effective after the US market closes on June 27, according to a preliminary list of additions posted on May 23. Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of April 30, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 Index or s

      6/3/25 8:00:06 AM ET
      $TOI
      Medical/Nursing Services
      Health Care
    • The Oncology Institute Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Guidance

      CERRITOS, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months ended March 31, 2025. Recent Operational Highlights Retail Pharmacy and Dispensary set fill records, contributing $49.3 million revenue and over $9 million in gross profit in Q1. The Pharmacy and Dispensary segment grew over 20% in the first quarter of 2025 vs. prior yearFee-for-service growth of 9% in Q1 2025 over Q4 2024, highlighting the impact of our investments in referral relationship management and call center expansion.Strong start

      5/14/25 4:06:58 PM ET
      $TOI
      Medical/Nursing Services
      Health Care
    • The Oncology Institute Welcomes Dr. Jeff Langsam as Chief Clinical Officer

      CERRITOS, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI"), one of the largest value-based oncology groups in the United States, announced today that Dr. Jeffrey Langsam will assume the role of enterprise Chief Clinical Officer effective May 13th, 2025. The CCO role will oversee therapeutics including pathway and procurement decisions, utilization management, and MSO practice clinical engagement. Dr. Langsam joins TOI from Cigna Healthcare, where he was the National Director of Oncology and a Senior Medical Director in the Specialty Pharmacy Division. He previously served as a Regional Medical Director at Aetna, and was clinical faculty at the Univ

      5/14/25 4:05:16 PM ET
      $TOI
      Medical/Nursing Services
      Health Care

    $TOI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hively Brad exercised 1,867,605 shares at a strike of $0.90 and sold $5,672,106 worth of shares (1,976,137 units at $2.87), decreasing direct ownership by 15% to 603,501 units (SEC Form 4)

      4 - Oncology Institute, Inc. (0001799191) (Issuer)

      6/5/25 6:51:15 PM ET
      $TOI
      Medical/Nursing Services
      Health Care
    • Chief Clinical Officer Langsam Jeffrey was granted 57,380 shares (SEC Form 4)

      4 - Oncology Institute, Inc. (0001799191) (Issuer)

      5/23/25 1:02:25 PM ET
      $TOI
      Medical/Nursing Services
      Health Care
    • SEC Form 3 filed by new insider Langsam Jeffrey

      3 - Oncology Institute, Inc. (0001799191) (Issuer)

      5/23/25 11:36:03 AM ET
      $TOI
      Medical/Nursing Services
      Health Care

    $TOI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Director Hively Brad bought $47,168 worth of shares (45,280 units at $1.04), increasing direct ownership by 7% to 712,033 units (SEC Form 4)

      4/A - Oncology Institute, Inc. (0001799191) (Issuer)

      4/28/25 7:20:14 PM ET
      $TOI
      Medical/Nursing Services
      Health Care
    • Chief Executive Officer Virnich Daniel bought $23,584 worth of shares (22,640 units at $1.04), increasing direct ownership by 3% to 724,363 units (SEC Form 4)

      4 - Oncology Institute, Inc. (0001799191) (Issuer)

      3/28/25 5:50:27 PM ET
      $TOI
      Medical/Nursing Services
      Health Care
    • Chief Medical Officer Podnos Yale bought $9,434 worth of shares (9,056 units at $1.04), increasing direct ownership by 13% to 79,049 units (SEC Form 4)

      4 - Oncology Institute, Inc. (0001799191) (Issuer)

      3/28/25 5:48:39 PM ET
      $TOI
      Medical/Nursing Services
      Health Care

    $TOI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by The Oncology Institute Inc.

      SC 13D/A - Oncology Institute, Inc. (0001799191) (Subject)

      8/20/24 8:20:55 AM ET
      $TOI
      Medical/Nursing Services
      Health Care
    • SEC Form SC 13D/A filed by The Oncology Institute Inc. (Amendment)

      SC 13D/A - Oncology Institute, Inc. (0001799191) (Subject)

      1/2/24 5:06:50 PM ET
      $TOI
      Medical/Nursing Services
      Health Care
    • SEC Form SC 13G/A filed by The Oncology Institute Inc. (Amendment)

      SC 13G/A - Oncology Institute, Inc. (0001799191) (Subject)

      7/10/23 10:20:11 AM ET
      $TOI
      Medical/Nursing Services
      Health Care

    $TOI
    SEC Filings

    See more
    • SEC Form S-3 filed by The Oncology Institute Inc.

      S-3 - Oncology Institute, Inc. (0001799191) (Filer)

      6/6/25 4:22:55 PM ET
      $TOI
      Medical/Nursing Services
      Health Care
    • SEC Form 144 filed by The Oncology Institute Inc.

      144 - Oncology Institute, Inc. (0001799191) (Subject)

      6/5/25 6:17:07 PM ET
      $TOI
      Medical/Nursing Services
      Health Care
    • SEC Form 144 filed by The Oncology Institute Inc.

      144 - Oncology Institute, Inc. (0001799191) (Subject)

      6/5/25 6:13:18 PM ET
      $TOI
      Medical/Nursing Services
      Health Care

    $TOI
    Financials

    Live finance-specific insights

    See more
    • The Oncology Institute Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Guidance

      CERRITOS, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months ended March 31, 2025. Recent Operational Highlights Retail Pharmacy and Dispensary set fill records, contributing $49.3 million revenue and over $9 million in gross profit in Q1. The Pharmacy and Dispensary segment grew over 20% in the first quarter of 2025 vs. prior yearFee-for-service growth of 9% in Q1 2025 over Q4 2024, highlighting the impact of our investments in referral relationship management and call center expansion.Strong start

      5/14/25 4:06:58 PM ET
      $TOI
      Medical/Nursing Services
      Health Care
    • The Oncology Institute Announces First Quarter 2025 Earnings Release Date and Conference Call

      CERRITOS, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI) one of the largest value-based oncology groups in the United States, today announced that the company will release its first quarter 2025 financial results after the market close on Wednesday, May 14, 2025, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and t

      4/23/25 8:00:46 AM ET
      $TOI
      Medical/Nursing Services
      Health Care
    • The Oncology Institute Reports Fourth Quarter and Full Year 2024 Financial Results and Guidance for 2025

      CERRITOS, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its fourth quarter and year ended December 31, 2024. Recent Operational Highlights Cash flow from operations in Q4 2024 was approximately $4.2 million, due to disciplined working capital management that saw improvements across receivables, inventory, and payables.Selling, general, and administrative expenses decreased 12% in Q4 2024 as compared to the prior year period, as a result of our ongoing efforts to streamline operations, improve efficiency, and o

      3/24/25 6:01:10 AM ET
      $TOI
      Medical/Nursing Services
      Health Care

    $TOI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research initiated coverage on The Oncology Institute with a new price target

      BTIG Research initiated coverage of The Oncology Institute with a rating of Buy and set a new price target of $7.00

      5/15/25 8:12:51 AM ET
      $TOI
      Medical/Nursing Services
      Health Care
    • Jefferies resumed coverage on The Oncology Institute with a new price target

      Jefferies resumed coverage of The Oncology Institute with a rating of Buy and set a new price target of $2.50

      2/26/24 8:25:21 AM ET
      $TOI
      Medical/Nursing Services
      Health Care
    • Guggenheim initiated coverage on The Oncology Institute with a new price target

      Guggenheim initiated coverage of The Oncology Institute with a rating of Buy and set a new price target of $7.00

      9/14/22 9:25:17 AM ET
      $TOI
      Medical/Nursing Services
      Health Care

    $TOI
    Leadership Updates

    Live Leadership Updates

    See more
    • The Oncology Institute set to join the Russell 2000® and Russell 3000® Indexes

      CERRITOS, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI"), one of the largest value-based oncology groups in the United States, today announced that it will join the Russell 2000® and Russell 3000® after the 2025 Russell indexes annual reconstitution, effective after the US market closes on June 27, according to a preliminary list of additions posted on May 23. Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of April 30, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 Index or s

      6/3/25 8:00:06 AM ET
      $TOI
      Medical/Nursing Services
      Health Care
    • Jordan McInerney Appointed as Chief Development Officer of The Oncology Institute

      CERRITOS, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. and its affiliates (NASDAQ:TOI) is pleased to announce the appointment of Jordan McInerney as the new Chief Development Officer (CDO), effective April 1, 2024. In this role, Mr. McInerney will spearhead growth initiatives for The Oncology Institute across diverse markets, including cultivating new partnerships with payors, driving M&A processes for acquisition targets, and establishing MSO platforms to deliver value-based oncology care nationwide. Bringing over 15 years of healthcare leadership, McInerney most recently served as the Chief Operations Officer of HOPCo Network Solutions, a subsidiary of Hea

      4/8/24 8:00:00 AM ET
      $TOI
      Medical/Nursing Services
      Health Care
    • The Oncology Institute Names Jeremy Castle as Chief Operations Officer

      CERRITOS, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) has announced the appointment of Jeremy Castle, MBA, as Chief Operations Officer, effective September 5, 2023. In this role, Mr. Castle leads enterprise field and central operations, pharmacy, real estate, and practice integration, playing a key role in driving TOI's success as a public company. Mr. Castle joins TOI with over 15 years of oncology industry experience, and has a track record of driving growth and profitability for multi-state physician groups. He has had other senior leadership positions, including Mr. Castle having previously served as the Chief Operating Officer for United Urolog

      10/11/23 4:05:00 PM ET
      $TOI
      Medical/Nursing Services
      Health Care